These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26699619)

  • 1. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
    Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
    PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
    Wu R; Chi X; Wang X; Sun H; Lv J; Gao X; Yu G; Kong F; Xu H; Hua R; Jiang J; Sun B; Zhong J; Pan Y; Niu J
    Infect Genet Evol; 2016 Apr; 39():132-140. PubMed ID: 26820907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.
    Knapp S; Zakaria Z; Hashem M; Zaghla H; Khakoo SI; Waked I; Thursz M; Abdelwahab SF
    Hepatol Int; 2015 Apr; 9(2):251-7. PubMed ID: 25788203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of interferon-lambda 4 ss469415590 with the hepatitis C virus treatment response and its comparison with interleukin 28b polymorphisms in predicting a sustained virological response: a meta-analysis.
    Li Y; Yang L; Sha K; Liu T; Zhang L
    Int J Infect Dis; 2016 Dec; 53():52-58. PubMed ID: 27810523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
    Eslam M; Leung R; Romero-Gomez M; Mangia A; Irving WL; Sheridan D; Spengler U; Mollison L; Cheng W; Bugianesi E; McLeod D; Zaitoun AM; Attino V; Goeltz D; Nattermann J; Douglas M; Booth DR; George J; Ahlenstiel G
    J Hepatol; 2014 Aug; 61(2):235-41. PubMed ID: 24768758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.
    Keshvari M; Alavian SM; Behnava B; Pouryasin A; Craig JC; Sharafi H
    J Clin Lab Anal; 2017 Jul; 31(4):. PubMed ID: 27735085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians.
    Real LM; Neukam K; Herrero R; Guardiola JM; Reiberger T; Rivero-Juarez A; Salazar J; Mandorfer M; Merino D; Soriano V; Rivero A; Macías J; Pineda JA; Caruz A
    PLoS One; 2014; 9(4):e95515. PubMed ID: 24748394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
    Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
    Thong VD; Wasitthankasem R; Tangkijvanich P; Vongpunsawad S; Poovorawan Y
    PLoS One; 2015; 10(5):e0125400. PubMed ID: 25938236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
    Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
    J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
    O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
    J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms.
    Nafari AH; Ayadi A; Noormohamadi Z; Sakhaee F; Vaziri F; Siadat SD; Fateh A
    Infect Genet Evol; 2020 Apr; 79():104144. PubMed ID: 31838260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
    Lin CY; Chen JY; Lin TN; Jeng WJ; Huang CH; Huang CW; Chang SW; Sheen IS
    PLoS One; 2011 Mar; 6(3):e18322. PubMed ID: 21479134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha.
    da Silva AMV; Alvarado-Arnez LE; Azamor T; Batista-Silva LR; Leal-Calvo T; Bezerra OCL; Ribeiro-Alves M; Kehdy FSG; Neves PCDC; Bayma C; da Silva J; de Souza AF; Muller M; de Andrade EF; Andrade ACM; Dos Santos EM; Xavier JR; Maia MLS; Meireles RP; Cuni HN; Sander GB; Picon PD; Matos DCS; Moraes MO
    Front Cell Infect Microbiol; 2021; 11():656393. PubMed ID: 34307188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.